Old Web
AR-V7 Variant Testing in Prostate Cancer Could Reduce Treatment Costs
2016
Determining the presence of AR-V7 in prostate cancer patients could potentially save the US healthcare system $150 million each year by preventing unnecessary treatment.
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI